Bris­tol My­er­s' Op­di­vo fails part two of post-kid­ney can­cer surgery test as com­peti­tor Mer­ck touts new sur­vival da­ta

Op­di­vo failed the sec­ond part of a piv­otal study for post-surgery kid­ney can­cer, re­searchers re­port­ed on Sat­ur­day.

Bris­tol My­ers Squibb’s check­point in­hibitor failed to im­prove dis­ease-free sur­vival com­pared to place­bo for pa­tients who re­ceived it for six months fol­low­ing surgery for re­nal cell car­ci­no­ma — the most com­mon form of kid­ney can­cer — ac­cord­ing to re­sults shared at the AS­CO Gen­i­touri­nary Can­cers Sym­po­sium. The re­sult comes af­ter the fail­ure of Op­di­vo plus Yer­voy, Bris­tol My­ers’ CT­LA-4-tar­get­ed im­munother­a­py, ver­sus place­bo in the first part of the tri­al called Check­Mate 914.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER